Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
212-Lead Pentixather in lung neuroendocrine tumors
NCT05557708Phase 1Not yet recruiting
- Start
- Jul 2026
- Primary completion
- Jun 2028
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [212Pb]-pentixather in Lung Neuroendocrine Tumor and small cell lung cancer (SCLC). Primary endpoint: Recommended Phase 2 Dose at 3 months. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
[212Pb]-pentixather
03
Conditions
Lung Neuroendocrine Tumorsmall cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05557708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05557708.